Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
MKS Instruments Analysts Await Elaboration On Ransomware Impact Post Q4 Results
Benchmark analyst Mark Miller had a Hold rating on MKS Instruments, Inc (NASDAQ:MKSI). For its 4Q22, MKS reported adjusted EPS of $2.00…